Free Trial
NASDAQ:OGI

Organigram Global Q2 2026 Earnings Report

Organigram Global logo
$1.38 -0.01 (-0.72%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$1.40 +0.02 (+1.45%)
As of 05/7/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organigram Global EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Organigram Global Revenue Results

Actual Revenue
N/A
Expected Revenue
$50.78 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Organigram Global Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Organigram Global Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Organigram Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organigram Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organigram Global and other key companies, straight to your email.

About Organigram Global

Organigram Global (NASDAQ:OGI) (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts. Organigram distributes under a variety of brands, including Monjour, Edison and First Growth, targeting diverse consumer segments from value-focused to premium. Its cultivation methods combine indoor and greenhouse systems with automated processes designed to ensure product consistency, safety and quality.

Organigram serves markets across Canada and has established partnerships to access select international markets in jurisdictions that recognize Canadian GMP certification. The company’s leadership team is led by Chief Executive Officer Greg Engel, who has guided Organigram through its public listings on the Toronto Stock Exchange and the Nasdaq in 2020. Under his management, Organigram has focused on innovation in product formats, efficiency in cultivation, and strategic brand development to navigate the evolving regulatory landscape.

View Organigram Global Profile